Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts.
I was reminded of this recently by a story that’s unfolding in the UK, where two asset-management firms are struggling a bit to hire CEOs. One is Scotland-based abrdn plc (SLFPF), whose shares have risen just 2.6% annually in the US on average over the last decade.
Compare that to a roughly 10% average year-to-date return enjoyed by the other major asset managers abrdn is competing with, and you get a good idea of what’s happening here: abrdn isn’t doing well enough to attract the best talent.
This is also visible in the performance of abrdn’s CEFs, particularly their total NAV return (shown at right below), or the performance of their underlying portfolios, including dividends received. This is a better measure of management performance than market-price-based returns, which are more sensitive to shareholder whims.
(If you’re a member of my CEF Insider service, you might recall that we sold the last of our abrdn CEFs, the abrdn Life Sciences Fund (HQL), abrdn Healthcare Opportunities Fund (THQ) and abrdn Total Dynamic Dividend Fund (AOD), in our January 2024 issue.)
Just like abrdn’s stock, abrdn’s funds are underperformers. With currently just a 7% total NAV return year to date as of this writing, management is underperforming the S&P 500 (up 16.2%) and global stocks, since the Vanguard Total World Stock ETF (VT) is up 11.9%.
As the firm struggles to fill the executive suite, there’s really no reason to suggest this will change anytime soon.
This is now a risk for abrdn CEFs, since CEFs can, and often do, trade at discounts to NAV. Of abrdn’s 16 managed CEFs, two trade at premiums. The best performer of those in the last five years is the abrdn Income Credit Strategies Fund (ACP), with a 1.2% premium. In other words, investors are paying above market price for abrdn’s ability to turn a profit with this fund.
ACP Disappoints Despite Premium Pricing
As you can see above, ACP has turned a profit over the last five years on a total NAV return basis, but just 7.5%. That’s an annualized total return of 0.45% per year—less than you’d get from a savings account.
With performances like that, it’s not surprising abrdn is struggling to fill the top job. Which also means that, until their record gets back on track, I’m struggling to see any reason to buy any fund the firm offers, especially if those priced at premiums.
What about discounted abrdn funds? Funny thing here is the markdown on abrdn’s most-discounted fund, the abrdn Japanese Equity Fund (JEQ), is actually quite reasonable.
The biggest appeal of JEQ should be its 16.9% discount to NAV as of this writing, far more than the 6.7% average discount across all CEFs on the market. Except that discount is unlikely to go anywhere soon, since JEQ (in purple below) underperforms the Japanese stock market, shown by the iShares MSCI Japan ETF (EWJ) in orange.
JEQ Keeps Lagging
Note how the gap between the orange and purple lines has widened in recent years.
This shows that while Japanese stocks are experiencing a renaissance, JEQ shareholders are being left behind.
Obviously, even the most discounted abrdn CEF still isn’t discounted enough, which means we need to look elsewhere for sustainable high yields and growth.
Alert: These Four 8.7% Payers Are Top Picks for the Rest of 2024 (and Beyond)
My top 4 CEFs to buy now yield an outsized 8.7% and are cheap now—so much so that I’m calling for 20%+ price gains from them in the next 12 months!
That’s in addition to those huge 8.7% payouts.
All 4 are smaller CEFs, which is where the biggest bargains are in the space: They’re plenty liquid for you and me to move in and out of—but too big for the institutional players to buy into.
As more individual investors discover these cheap high yields (especially with interest rates set to fall), I expect them to soar, booking that forecast 20%+ gain I just mentioned.
Click here and I’ll share more details on each of them with you and explain more about why CEFs are (for now) so far off the radar. You’ll also get to download a FREE Special Report naming all 4 of these funds, including their tickers, current yields, discounts and everything else you need to get in on them now, while they’re still cheap.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.